Illumina is developing an AI strategy centered on biological data from its sequencing technology. The company's initiatives, including the Billion Cell Atlas and expanded drugmaker partnerships, could create a new growth engine if it successfully converts its scientific advantages into recurring commercial revenue.
Axe note: Illumina’s push into AI-fueled biology offers growth potential but lacks direct South African exposure, making USD/ZAR the smarter local play.